Biblio

Export 21 results:
Author Title Type Year
Filters: First Letter Of Keyword is A and Author is Vellas, Bruno  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Activities of Daily Living
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
C. Reed, Happich, M., Argimon, J. Maria, Haro, J. Maria, Wimo, A., Bruno, G., Dodel, R., Jones, R. W., Vellas, B., and Belger, M., “What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study.”, J Alzheimers Dis, vol. 57, no. 3, pp. 797-812, 2017.
Aged
N. Voyle, Keohane, A., Newhouse, S., Lunnon, K., Johnston, C., Soininen, H., Kloszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., Hodges, A., Kiddle, S., and Dobson, R. Jb, “A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis.”, J Alzheimers Dis, vol. 49, no. 3, pp. 659-69, 2016.
M. Sattlecker, Khondoker, M., Proitsi, P., Williams, S., Soininen, H., Kłoszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., and Dobson, R. Jb, “Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1105-14, 2016.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
A. Jacquin-Piques, Sacco, G., Tavassoli, N., Rouaud, O., Bejot, Y., Giroud, M., Robert, P., Vellas, B., and Bonin-Guillaume, S., “Psychotropic Drug Prescription in Patients with Dementia: Nursing Home Residents Versus Patients Living at Home.”, J Alzheimers Dis, vol. 49, no. 3, pp. 671-80, 2016.
C. Reed, Happich, M., Argimon, J. Maria, Haro, J. Maria, Wimo, A., Bruno, G., Dodel, R., Jones, R. W., Vellas, B., and Belger, M., “What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study.”, J Alzheimers Dis, vol. 57, no. 3, pp. 797-812, 2017.
Aged, 80 and over
N. Voyle, Keohane, A., Newhouse, S., Lunnon, K., Johnston, C., Soininen, H., Kloszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., Hodges, A., Kiddle, S., and Dobson, R. Jb, “A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis.”, J Alzheimers Dis, vol. 49, no. 3, pp. 659-69, 2016.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
A. Jacquin-Piques, Sacco, G., Tavassoli, N., Rouaud, O., Bejot, Y., Giroud, M., Robert, P., Vellas, B., and Bonin-Guillaume, S., “Psychotropic Drug Prescription in Patients with Dementia: Nursing Home Residents Versus Patients Living at Home.”, J Alzheimers Dis, vol. 49, no. 3, pp. 671-80, 2016.
C. Reed, Happich, M., Argimon, J. Maria, Haro, J. Maria, Wimo, A., Bruno, G., Dodel, R., Jones, R. W., Vellas, B., and Belger, M., “What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study.”, J Alzheimers Dis, vol. 57, no. 3, pp. 797-812, 2017.
Alzheimer Disease
N. Voyle, Keohane, A., Newhouse, S., Lunnon, K., Johnston, C., Soininen, H., Kloszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., Hodges, A., Kiddle, S., and Dobson, R. Jb, “A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis.”, J Alzheimers Dis, vol. 49, no. 3, pp. 659-69, 2016.
M. Sattlecker, Khondoker, M., Proitsi, P., Williams, S., Soininen, H., Kłoszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., and Dobson, R. Jb, “Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1105-14, 2016.
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L., “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
C. Reed, Happich, M., Argimon, J. Maria, Haro, J. Maria, Wimo, A., Bruno, G., Dodel, R., Jones, R. W., Vellas, B., and Belger, M., “What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study.”, J Alzheimers Dis, vol. 57, no. 3, pp. 797-812, 2017.
Amyloid beta-Peptides
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Analysis of Variance
C. Reed, Happich, M., Argimon, J. Maria, Haro, J. Maria, Wimo, A., Bruno, G., Dodel, R., Jones, R. W., Vellas, B., and Belger, M., “What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study.”, J Alzheimers Dis, vol. 57, no. 3, pp. 797-812, 2017.
Antibodies, Monoclonal, Humanized
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
Apolipoproteins E
N. Voyle, Keohane, A., Newhouse, S., Lunnon, K., Johnston, C., Soininen, H., Kloszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., Hodges, A., Kiddle, S., and Dobson, R. Jb, “A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis.”, J Alzheimers Dis, vol. 49, no. 3, pp. 659-69, 2016.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.